Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications
X Zhong, X He, Y Wang, Z Hu, H Huang, S Zhao… - Journal of hematology & …, 2022 - Springer
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer-related death worldwide. Countless CRC patients undergo disease progression. As …
cancer-related death worldwide. Countless CRC patients undergo disease progression. As …
Targeting cancer metabolism in the era of precision oncology
One hundred years have passed since Warburg discovered alterations in cancer
metabolism, more than 70 years since Sidney Farber introduced anti-folates that …
metabolism, more than 70 years since Sidney Farber introduced anti-folates that …
Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation
C Schiliro, BL Firestein - Cells, 2021 - mdpi.com
Cancer cells alter metabolic processes to sustain their characteristic uncontrolled growth
and proliferation. These metabolic alterations include (1) a shift from oxidative …
and proliferation. These metabolic alterations include (1) a shift from oxidative …
ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer
S Dong, S Liang, Z Cheng, X Zhang, L Luo, L Li… - Journal of Experimental …, 2022 - Springer
Background Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in
colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have …
colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have …
Metabolic reprogramming in cancer: Mechanisms and therapeutics
S Nong, X Han, Y **ang, Y Qian, Y Wei, T Zhang… - MedComm, 2023 - Wiley Online Library
Cancer cells characterized by uncontrolled growth and proliferation require altered
metabolic processes to maintain this characteristic. Metabolic reprogramming is a process …
metabolic processes to maintain this characteristic. Metabolic reprogramming is a process …
Targeting the HIF2–VEGF axis in renal cell carcinoma
TK Choueiri, WG Kaelin Jr - Nature medicine, 2020 - nature.com
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …
Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
AF Abdel-Wahab, W Mahmoud, RM Al-Harizy - Pharmacological research, 2019 - Elsevier
Most solid tumor cells adapt to their heterogeneous microenvironment by depending largely
on aerobic glycolysis for energy production, a phenomenon called the Warburg effect, which …
on aerobic glycolysis for energy production, a phenomenon called the Warburg effect, which …
3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs
AS Nunes, AS Barros, EC Costa… - Biotechnology and …, 2019 - Wiley Online Library
Three‐dimensional cell culture models, such as spheroids, can be used in the process of the
development of new anticancer agents because they are able to closely mimic the main …
development of new anticancer agents because they are able to closely mimic the main …
Signal pathways and precision therapy of small-cell lung cancer
M Yuan, Y Zhao, HT Arkenau, T Lao, L Chu… - Signal Transduction and …, 2022 - nature.com
Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients,
but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings …
but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings …